Crossmark

Injectable synthetic bone graft substitute (GeneX) in the surgical management of benign bone tumours: further experience from a tertiary musculoskeletal oncology centre

Crossref DOI link: https://doi.org/10.1007/s00590-025-04655-0

Published Online: 2026-02-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McAuley, Joseph J

Razii, Nima

Clark, Jack O

Mahendra, Ashish

Gupta, Sanjay
License Information

Text and Data Mining valid from 2026-02-10

Version of Record valid from 2026-02-10
More Information

Article History

Received: 3 October 2025

Accepted: 27 December 2025

First Online: 10 February 2026

Declarations

:

: The authors declare no competing interests. No funds, grants, or other support was received from any organization for the submitted work.

Document is current

Any future updates will be listed below